公开(公告)号：US07482130B2

公开(公告)日：2009-01-27

申请号：US11460588

申请日：2006-07-27

Applicant: Yasumichi Hitoshi ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Yonchu Jenkins

IPC: G01N33/574 ,  A61K38/00

CPC classification number: G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/6872 ,  G01N2333/4703

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract translation: 本发明涉及细胞增殖的调控。 更具体地，本发明涉及编码NP95的核酸，其涉及细胞周期停滞的调节。 本发明还涉及用于鉴定和使用通过调节NP95来调节细胞周期阻滞的试剂，包括小分子化学组成，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶的方法; 以及在细胞周期调控和细胞增殖调节相关的诊断和治疗中使用表达谱和组合物，例如用于治疗癌症和其它细胞增殖疾病。

公开(公告)号：US07358040B2

公开(公告)日：2008-04-15

申请号：US10026331

申请日：2001-12-21

Applicant: Yasumichi Hitoshi ,  Susan Demo ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Susan Demo ,  Yonchu Jenkins

IPC: C12Q1/00

CPC classification number: C12Q1/34 ,  G01N33/5011 ,  G01N33/573 ,  G01N2333/922 ,  G01N2500/02

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.

Abstract translation: 本发明涉及细胞增殖的调控。 更具体地，本发明涉及编码MRE11的核酸，其是涉及细胞增殖调节的蛋白质。 本发明还涉及用于鉴定和使用通过调节MRE11来调节细胞增殖的试剂，包括小分子化学组合物，抗体，肽，环肽，核酸，反义核酸和核酶的方法; 以及在与调节细胞增殖相关的诊断和治疗中使用表达谱和组合物。

公开(公告)号：US20070128673A1

公开(公告)日：2007-06-07

申请号：US11460588

申请日：2006-07-27

Applicant: Yasumichi Hitoshi ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Yonchu Jenkins

IPC: G01N33/574

CPC classification number: G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/6872 ,  G01N2333/4703

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract translation: 本发明涉及细胞增殖的调控。 更具体地，本发明涉及编码NP95的核酸，其涉及细胞周期停滞的调节。 本发明还涉及用于鉴定和使用通过调节NP95来调节细胞周期阻滞的试剂，包括小分子化学组成，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶的方法; 以及在细胞周期调控和细胞增殖调节相关的诊断和治疗中使用表达谱和组合物，例如用于治疗癌症和其它细胞增殖疾病。

公开(公告)号：US07413870B2

公开(公告)日：2008-08-19

申请号：US10026021

申请日：2001-12-21

Applicant: Yasumichi Hitoshi ,  Susan Demo ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Susan Demo ,  Yonchu Jenkins

IPC: C12Q1/50

CPC classification number: G01N33/57484 ,  A61K38/00 ,  A61K2039/505 ,  G01N2333/912

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract translation: 本发明涉及细胞增殖的调控。 更具体地，本发明涉及编码SAK的核酸，其是参与调节细胞增殖和细胞周期调节的蛋白激酶。 本发明还涉及用于鉴别和使用通过调节SAK调节细胞周期调节和细胞增殖的试剂，包括小分子化学组合物，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶的方法; 以及在细胞周期调控和细胞增殖调节相关的诊断和治疗中使用表达谱和组合物，例如用于治疗癌症和其它细胞增殖疾病。

公开(公告)号：US20060051755A1

公开(公告)日：2006-03-09

申请号：US10510903

申请日：2003-04-15

Applicant: Yasumichi Hitoshi ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Yonchu Jenkins

IPC: C12Q1/68

CPC classification number: G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2500/00

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract translation: 本发明涉及细胞增殖的调控。 更具体地，本发明涉及编码BRCA-1相关蛋白-1（BAP-1），核蛋白95（NP95），Fanconi贫血A组蛋白（FANCA），DEAD / H盒多肽9（DDX9） ），胰岛素样生长因子1受体（IGF1R），泛素结合酶E2变体1（UBE2V1），醛脱氢酶，丙酮酸激酶，葡萄糖-6-磷酸脱氢酶，HCDR-3，DEAD / H盒多肽21（DDX21） ，丝氨酸苏氨酸激酶15（ARK2），跨膜4超家族成员1或ERCC1，其参与调节细胞周期停滞。 本发明还涉及用于鉴定和使用包括小分子化学组合物，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶在内的试剂的方法，其通过调节BRCA-1相关的调节细胞周期阻滞 蛋白-1（BAP-1），核蛋白95（NP95），Fanconi贫血组A蛋白（FANCA），DEAD / H盒多肽9（DDX9），胰岛素样生长因子1受体（IGF1R），泛素缀合酶 E2变体1（UBE2V1），醛脱氢酶，丙酮酸激酶，葡萄糖-6-磷酸脱氢酶，HCDR-3，DEAD / H盒多肽21（DDX21），丝氨酸苏氨酸激酶15（ARK2），跨膜4超家族成员1或ERCC1 ，以及在与细胞周期调节和细胞增殖调节相关的诊断和治疗中使用表达谱和组合物，例如用于治疗癌症和其他细胞增殖疾病。

公开(公告)号：US20150087673A1

公开(公告)日：2015-03-26

申请号：US14498921

申请日：2014-09-26

Applicant: Yasumichi Hitoshi ,  Yonchu Jenkins ,  Vadim Markovtsov ,  Todd Kinsella ,  Tian-Qiang Sun

Inventor： Yasumichi Hitoshi ,  Yonchu Jenkins ,  Vadim Markovtsov ,  Todd Kinsella ,  Tian-Qiang Sun

IPC: A61K31/4545 ,  C07D401/14 ,  A61K45/06 ,  G01N33/573

CPC classification number: A61K31/4545 ,  A61K31/4427 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  G01N33/573 ,  G01N2500/04 ,  A61K2300/00

Abstract: Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D1, D2, D3, the ring system denoted by “B”, T, R3, R4, w and x are as described herein.

Abstract translation: 公开了使用AMPK活化化合物的方法，例如用于治疗癌症和血管流动障碍。 还公开了AMPK的生物标志物及其用途，例如在AMPK相关疾病的诊断和治疗中。 在某些实施方案中，AMPK活化化合物具有其结构式，其中E，J，T，D1，D2，D3，由“B”，T，R3，R4，w和x表示的环系统如本文所述。

公开(公告)号：US07090990B2

公开(公告)日：2006-08-15

申请号：US10123568

申请日：2002-04-15

Applicant: Yasumichi Hitoshi ,  Yonchu Jenkins

Inventor： Yasumichi Hitoshi ,  Yonchu Jenkins

IPC: G01N33/574

CPC classification number: G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/6872 ,  G01N2333/4703

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

公开(公告)号：US08791136B2

公开(公告)日：2014-07-29

申请号：US13194810

申请日：2011-07-29

Applicant: Dane Goff ,  Donald Payan ,  Rajinder Singh ,  Simon Shaw ,  David Carroll ,  Yasumichi Hitoshi

Inventor： Dane Goff ,  Donald Payan ,  Rajinder Singh ,  Simon Shaw ,  David Carroll ,  Yasumichi Hitoshi

IPC: A61K31/4427 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07B2200/07 ,  C07D213/56 ,  C07D213/81 ,  C07D213/82 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/06 ,  C07D471/10 ,  C07D487/04 ,  C07D495/04

Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

Abstract translation: 公开了取代的吡啶化合物以及药物组合物和使用方法。 一个实施方案是具有其中E，J，T，由“B”，T，R3，R4，w和x表示的环系统如本文所述的结构的化合物。 在某些实施方案中，本文公开的化合物激活AMPK途径，并且可用于治疗与代谢有关的病症和病症。

公开(公告)号：US08546433B2

公开(公告)日：2013-10-01

申请号：US12688746

申请日：2010-01-15

Applicant: Yasumichi Hitoshi ,  Sacha Holland ,  Donald G. Payan

Inventor： Yasumichi Hitoshi ,  Sacha Holland ,  Donald G. Payan

IPC: A01N43/64 ,  A61K31/41 ,  C07D413/00

CPC classification number: A61K31/502 ,  A61K31/4196 ,  A61K33/24 ,  A61K45/06 ,  C07D403/04 ,  C07D403/14 ,  A61K2300/00

Abstract: This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.

Abstract translation: 本发明涉及在患者体内预防，治疗或控制癌症，优选转移性癌症的方法。 所述方法包括与施用有效量的一种或多种化学治疗剂组合施用有效量的Axl抑制剂。

公开(公告)号：US20180057478A1

公开(公告)日：2018-03-01

申请号：US15603023

申请日：2017-05-23

Applicant: Dane Goff ,  Donald Payan ,  Rajinder Singh ,  Simon Shaw ,  David Carroll ,  Yasumichi Hitoshi

Inventor： Dane Goff ,  Donald Payan ,  Rajinder Singh ,  Simon Shaw ,  David Carroll ,  Yasumichi Hitoshi

IPC: C07D401/14 ,  C07D213/82 ,  C07D405/12 ,  C07D213/56 ,  C07D213/81 ,  C07D495/04 ,  C07D487/04 ,  C07D471/10 ,  C07D451/06 ,  C07D417/14 ,  C07D413/14 ,  C07D409/14 ,  C07D409/12 ,  C07D405/14 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04

CPC classification number: C07D401/14 ,  C07B2200/07 ,  C07D213/56 ,  C07D213/81 ,  C07D213/82 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/06 ,  C07D471/10 ,  C07D487/04 ,  C07D495/04

Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.